OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.
Georges Gemayel has served as Chairman for OxThera since October 2013. From February 2011 to December 2012, Dr. Gemayel served as executive chairman of Syndexa Pharmaceuticals Corp., a privately held drug development company. Prior to that, in 2010 Dr. Gemayel served as executive chairman of FoldRx Pharmaceuticals, Inc. until its acquisition by Pfizer Inc. From June 2008 until November 2009, Dr. Gemayel served as president and chief executive officer of Altus Pharmaceuticals Inc., a publicly traded pharmaceutical company. From 2003 to 2008, he was executive vice president at Genzyme Corporation where he was responsible for Genzyme Corporation’s global therapeutics, transplant, renal and biosurgery businesses. Dr. Gemayel currently serves as chairman of the boards of directors of Enterome Bioscience SA and Orphazyme ApS, both privately held companies, and on the boards of directors of Dimension Therapeutics, Momenta Pharmaceuticals, and Supernus Pharmaceuticals, Inc.
Dr. Gemayel received his doctorate in pharmacy from St. Joseph University in Beirut, Lebanon and his Ph.D. in pharmacology from Paris-Sud University in Paris, France.
Martijn Kleijwegt founded Life Sciences partners (LSP) in 1998 and is currently a Managing Partner and co-owner of the firm. His prime focus and responsibility within LSP is to invest in unlisted securities and in the general management of the firm. Prior to establishing LSP, Martijn ran another investment firm where he was responsible for investments in the healthcare sector. As one of Europe’s most experienced healthcare investors, Martijn brings over 30 years of hands-on finance and investment experience to the LSP team. He has also been appointed Director of a large number of companies, amongst others Qiagen GmbH, Crucell N.V., Movetis N.V., Prosensa Holding N.V. and Kiadis Pharma, all of which he helped to grow and flourish.
Managing Partner at Kurma Partners, Rémi was previously Partner at Idinvest Partners where he developed investment activity in the life sciences. Rémi serves on the board of AM Pharma, Bioalliance Pharma (listed on Euronext) and STAT Diagnostica. He holds a MS in molecular biology (Paris VI University) and MS in finance and Innovation management (AgroPariTech).
Lance is a Venture Partner at Ysios and brings over 20 years of clinical development, medical affairs and corporate leadership experience in both the big pharma and small biotech start-up spaces. Prior to joining Ysios, Lance was Chief Medical Officer and Senior Vice President at Relypsa in the San Francisco Bay area where he was responsible for building and leading the Company’s clinical development, medical affairs and drug safety functions; as well as playing a key role in the preparation and execution of the Company’s fund-raising initiatives including the Company’s IPO. Under his clinical leadership, the Company secured FDA and EMA approval for VeltassaÒ. Prior to Relypsa Lance was Chief Medical Officer at CPEX Pharmaceuticals until its acquisition. Previously, Lance held roles of increasing responsibility at Pfizer Inc., Schering-Plough Corporation (merged with Merck) and at Janssen Pharmaceuticals, Inc. (Johnson & Johnson). In addition to having worked across multiple therapeutic areas, he has also worked closely with commercial teams to secure product reimbursement and to plan and execute product launches. Lance received his Bachelor of Medicine and Bachelor of Surgery degree from the University of Cape Town, South Africa and holds a Master’s in Science (Pharmaceutical Medicine).
Dr. Verland is a Partner of Sunstone Life Science Ventures and one of the three co-founders of Sunstone. Dr. Verland has been active as a serial entrepreneur and business angel and has co-founded ten start-ups, primarily in the biotech and CRO fields. Dr. Verland has played a key role in executing two M&As (Action Pharma and Zymenex). He currently serves on the Board of Directors of Orphazyme A/S, Rigontec GmbH, Vaximm AG, Anergis SA, Minervax APS and the Danish Venture Capital Association, as well as an observer to the Board of Directors of F2G Ltd.
Dr. Verland holds a Master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen.
Co-founder and CEO of Cormorant Pharmaceuticals developing an immuno-oncology mAb, acquired by Bristol-Myers Squibb in 2016. Prior to that, Medical Director at Swedish Orphan Biovitrum, with medical/clinical development responsibility for two marketed products in the rare disease space. Worked in clinical development at Sanofi and also as a financial analyst at two investment banks for five years.
Investment Manager Life Science at Industrifonden. Dr Brambeck has close to twenty years experience from venture capital within Life Science. He serves on the Board of Directors of Oncopeptides AB, OxThera AB and Athera Biotechnologies AB. He holds a Ph.D. in organic chemistry from The Royal Institute of Technology in Stockholm.
Alain has an MD in Cardiology and Anesthesiology and was the head of the Cardiology department at the University Hospital of Montpellier-Nimes. Alain has numerous publications and has been a member of the scientific committee of the French Drug Agency. Alain has over 25 years experience in the pharmaceutical industry as a senior executive within the Sanofi Group and with Fournier Laboratories. He has an in-depth knowledge of the EU, US and Japanese regulatory process and markets. Under his leadership numerous NDA’s were obtained world-wide (Adenocard®, Plavix®, Lipanthyl®/Tricor™, Esclim®, Ikervis®) Alain is Chairman of the Strategic Board of Hybrigenics (ALHYG.PA), a board member of Valneva SE (VLA), a board member of Zealand Pharma (ZEAL),and adviser to KURMA Biofund.
CEO of OxThera AB. Former PathoGenesis, Chiron and BTG executive, who has built and led several successful high growth businesses in the US and Europe across the specialty pharma and medical device space in multiple therapeutic areas. Gained approval and successfully launched two rare disease drugs, TOBI and Voraxaze, in Europe and US respectively. Board member of SOBI, a publically listed Swedish Rare Disease Company and Life Sciences PA, the Pennsylvania Life Science industry association.
Mr Gantz is a graduate of Princeton University and received his MBA from Harvard Business School. He also served as an infantry officer in the US Marine Corps.
COO of OxThera AB. Member of the Royal Swedish Academy of Engineering Sciences. Mrs Lindner has long-term senior management experience from Pharmacia Corporation, Octapharma, and Diamyd Medical among others. She also serves on the Board of Directors for Cobra Biologics Holding AB. Mrs Lindner holds a MSc from the Royal Institute of Technology and a MBA from Uppsala University.
Chief Medical Officer of OxThera AB. Dr Dehmel has extensive experience in the life science sector, having led Medical Affairs and Clinical Development teams responsible for drugs in Diabetes and End Stage Renal Disease at companies like GSK, Novo Nordisk and Amgen. Dr Dehmel joins OxThera after serving as Executive Medical Director and Global Development Leader for Amgen’s calcimimetic franchise. He brings extensive experience in working with global regulatory agencies and was responsible for FDA and EMA approval of etelcalcetide, and more recently for the orphan pediatric drug approval of cinacalcet by EMA. Dr Dehmel received his medical training in Internal Medicine while at the Charite University in Berlin.
OxThera is supported by a strong group of international life science investors including: